Eli Lilly (LLY)
930.35
-58.77 (-5.94%)
NYSE · Last Trade: Mar 17th, 6:53 PM EDT
Detailed Quote
| Previous Close | 989.12 |
|---|---|
| Open | 978.92 |
| Bid | 930.10 |
| Ask | 930.32 |
| Day's Range | 925.25 - 981.17 |
| 52 Week Range | 623.78 - 1,133.95 |
| Volume | 5,633,317 |
| Market Cap | 889.96B |
| PE Ratio (TTM) | 40.54 |
| EPS (TTM) | 22.9 |
| Dividend & Yield | 6.920 (0.74%) |
| 1 Month Average Volume | 2,784,434 |
Chart
About Eli Lilly (LLY)
Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
News & Press Releases

Today, March 17, 2026, selective tech gains helped lift the Nasdaq even as oil prices and geopolitical tensions stayed elevated.
Via The Motley Fool · March 17, 2026
What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 6.3% in the afternoon session after investment bank HSBC downgraded the stoc...
Via StockStory · March 17, 2026
You don't have to go all in to profit from AI.
Via The Motley Fool · March 17, 2026
Which S&P500 stocks are moving on Tuesday?chartmill.com
Via Chartmill · March 17, 2026
The analyst’s new price target represents a potential downside of about 14% from the stock’s last closing price on Monday.
Via Stocktwits · March 17, 2026

Eli Lilly's stock price is based on growth rates that might fall short.
Via The Motley Fool · March 17, 2026
Tuesday's session: top gainers and losers in the S&P500 indexchartmill.com
Via Chartmill · March 17, 2026
HSBC downgrades Eli Lilly to reduce, citing pricing pressure, rising competition, and overestimated obesity drug market growth expectations.
Via Benzinga · March 17, 2026
Novo Nordisk recently announced promising trial results for one of its GLP-1 drugs in development.
Via The Motley Fool · March 17, 2026
Tuesday's session: gap up and gap down stock in the S&P500 indexchartmill.com
Via Chartmill · March 17, 2026
Pfizer has reached a turning point.
Via The Motley Fool · March 17, 2026
Eli Lilly's stock is down this year, and its high valuation may be a big reason why.
Via The Motley Fool · March 16, 2026
Amidst a backdrop of mounting geopolitical tensions and sharp swings in the broader indices, pharmaceutical giant Merck & Co. (NYSE: MRK) officially trades ex-dividend today, March 16, 2026. Investors who held the stock prior to today’s session are now locked in to receive a quarterly payout of $0.85 per
Via MarketMinute · March 16, 2026
The drama and uncertainty around Novo Nordisk and Hims & Hers Health might finally be ending.
Via The Motley Fool · March 16, 2026
Eli Lilly's Phase 3 results for Ebglyss in children with severe eczema, shows skin clearance and itch relief in trial patients.
Via Benzinga · March 16, 2026
Quality compounders are flywheels. Said differently, they’re businesses that generate heaps of profits and consistently reinvest them to produce even more pr...
Via StockStory · March 16, 2026

This biotech firm develops therapies targeting cystic fibrosis, with shares up nearly 90% year-over-year as of the latest filing.
Via The Motley Fool · March 15, 2026

RAPT Therapeutics develops oral therapies for cancer and inflammation, with key drug candidates currently in clinical trials.
Via The Motley Fool · March 15, 2026
Via MarketBeat · March 15, 2026
It won't be easy to knock the company off its pedestal.
Via The Motley Fool · March 13, 2026
As the first quarter of 2026 unfolds, the euphoric bull market that defined the mid-2020s has hit a formidable wall of uncertainty. A potent cocktail of geopolitical instability in the Middle East and South America, coupled with a domestic crisis of confidence in central bank leadership, has sent major indices
Via MarketMinute · March 13, 2026
In a day marked by heightened global tensions and a sharp spike in energy prices, the U.S. equity markets witnessed a decisive "Great Rotation" as investors abandoned high-growth technology names in favor of battle-tested stalwarts. On Friday, March 13, 2026, JPMorgan Chase & Co. (NYSE: JPM) and Eli Lilly and
Via MarketMinute · March 13, 2026
Via MarketBeat · March 13, 2026